Newsroom

PERTH, Australia--(BUSINESS WIRE)--The Rhodes Ridge Joint Venture has approved a $191 million (A$294 million) (Rio Tinto share $96 million, A$147 million) feasibility study to progress development of the first phase of the Rhodes Ridge project, one of the world’s best undeveloped iron ore deposits, in Western Australia’s Pilbara. The feasibility study will assess development of an operation with initial annual production capacity of 40 to 50 million tonnes of iron ore. The joint venture partner...

NEW YORK--(BUSINESS WIRE)--JPMorgan Chase & Co. (NYSE: JPM) (“JPMorganChase” or the “Firm”) has declared dividends on the outstanding shares of the Firm’s Series CC preferred stock. Information can be found on the Firm’s Investor Relations website at https://www.jpmorganchase.com/ir/news. JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in the United States of America (“U.S.”), with operations worldwide. JPMorganChase had $4.6 trillion in assets and $360 billi...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 12, 2025, the Company’s Board of Directors approved “inducement” grants to 78 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 141,310 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and...

CALGARY (Alberta)--(BUSINESS WIRE)--L’Impériale (TSE : IMO, NYSE American : IMO) a communiqué aujourd’hui ses prévisions pour 2026. La stratégie de la compagnie reste axée sur l’optimisation de la valeur de ses actifs existants et l’avancement d’occasions de croissance avantageuses à forte valeur tout en offrant à ses actionnaires des rendements parmi les meilleurs de l’industrie. « Notre plan pour 2026 s’appuie sur les bases solides de L’Impériale et positionne l’entreprise de manière à augmen...

NEW YORK--(BUSINESS WIRE)--BlackRock Corporate High Yield Fund, Inc. (NYSE: HYT) (the "Fund") today announced the terms of transferable rights ("Rights") to be issued to the holders of the Fund's common stock (par value $0.10 per share) ("Shares") as of January 2, 2026 (the "Record Date"). Holders of Rights will be entitled to subscribe for additional Shares (the "Offer") at a discount to the market price of the Shares. After considering a number of factors, including potential benefits and cos...

ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today confirmed the company will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The company’s leadership team will host investor meetings on Wednesday, January 14th, and present at 4:30 p.m. PT the same day. A live audio webcast of the session will be available at https://investors.guardianpharmacy.com. A replay will be accessible shortly after the event and will remain available for...

LEXINGTON, Ky.--(BUSINESS WIRE)--Valvoline Inc. (NYSE: VVV), the quick, easy, trusted leader in preventive automotive maintenance today released findings of its 2025-2026 winter driving preparedness survey. The nationwide study of 1,000 U.S. drivers reveals that many Americans may be entering the cold-weather driving season less prepared than they think. According to the survey, more than half 62% of drivers have experienced a cold-weather breakdown at least once, and 58% of drivers have lost c...

CALGARY, Alberta--(BUSINESS WIRE)--Imperial (TSE: IMO, NYSE American: IMO) today provided its corporate guidance outlook for 2026. The company’s strategy remains focused on maximizing the value of its existing assets and progressing advantaged high-value growth opportunities while delivering industry-leading returns to shareholders. “Our 2026 plan builds on Imperial’s strong foundation and positions the company to structurally increase cash flow, by progressing towards volume and unit cash cost...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, as determined by a Food and Drug Administration (FDA)-approved test. The approval follows Priority Review and Breakthrough Therapy Designation by the FDA and is based on the results of the DESTINY-Breast09 Phase III trial....

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21st to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson &...